CD274 and non-small cell lung carcinoma: In a randomized phase II trial in patients with unresectable stage III non-small cell lung cancer (NSCLC) and no progression after concurrent chemo-radiotherapy, combining oleclumab with durvalumab (a Fc optimized IgG1κ monoclonal antibody directed against PD-L1) increased objective response rate and 12-month progression-free survival (PFS) compared to durvalumab alone12.